-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $55

Benzinga·02/11/2026 15:29:45
Listen to the news
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $46 to $55.